Search Results
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
August, 2024
August 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jul
ASCO
Apr 25, 2024, 21:06 |
Drugs
Piotr Wysocki: Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "Datopotamab deruxtecan – a novel anti-TROP2 conjugate demonstrates activity…
Apr 25, 2024, 20:52 |
Dialogues
Oncothon: Pediatric Cancer Drug Development
Oncothon is a telethon spanning 24 hours, dedicated to gathering donations for childhood cancer research.…
Apr 25, 2024, 19:32 |
Blog
Janice Cowden: We need your voice
Janice Cowden shared on LinkedIn: "Are you a cancer Patient, Research, Policy or Community advocate? Are…
Apr 25, 2024, 19:25 |
Blog
Khalid El Bairi interview with Dr Ouissam Al Jarroudi (MD)
Khalid El Bairi, International Executive Council at NCODA, shared on LinkedIn: "Dr Ouissam Al Jarroudi (MD)…
Apr 25, 2024, 14:18 |
Career
Gevorg Tamamyan: It is an extreme honor being elected as the President-Elect of SIOP Asia
Gevorg Tamamyan shared on LinkedIn: "It is an extreme honor being elected as the President-Elect of…
Apr 25, 2024, 12:40 |
Drugs
Piotr Wysocki: Similar activity of topotecan and liposomal irinotecan in second-line treatment of SCLC
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 24, 2024, 22:02 |
Blog
Michael Shusterman: Just a reminder about why we should NOT use bolus 5-FU in combination with the infusion
Michael Shusterman, Medical oncologist and Clinical Assistant Professor of Medicine in the Permutter Cancer Center…
Apr 24, 2024, 10:38 |
Insight
Khalid El Bairi: My interview with Ouissam Al Jarroudi, one of the leading experts in breast cancer in Morocco
Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared on LinkedIn: “Ouissam Al…
Apr 24, 2024, 09:13 |
Drugs
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
FDA, the Food and Drug Administration, approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) with…
Apr 23, 2024, 23:25 |
Drugs
Jarushka Naidoo: Pooled 5-year outcomes of Pembrolizumab and Chemotherapy for PDL less than 1% metastatic NSCLC in the Journal of Thoracic Oncology
Jarushka Naidoo shared on X: “Pooled 5-yr outcomes of Pembrolizumab and Chemotherapy for PDL1<1% metastatic…
223
224
225
226
227
All:
2850
Posts:
2241 - 2250
Naoto Ueno: I am honored to present my candidacy for the UICC Board of Directors
New management team at St. Anna Children's Hospital
Key Inspirational Moments with WHO Director at the Olympic Games
Remembering Susan Wojcicki, Honoring a Legacy of Leadership and Technological Innovation
MASCC24 Highlights: The Ideal Location for Care Varies According to Disease, Patient and Family Characteristics
Facebook
RSS Feed
Twitter
Linkedin
Youtube